We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 125

Snapshot of Sunshine rules in EU countries for the pharmaceutical industry part 1 - June 2014
  • McDermott Will & Emery
  • European Union, United Kingdom
  • June 12 2014

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. In 2013


Controlling and processing data in EU clinical trials
  • McDermott Will & Emery
  • European Union
  • November 22 2010

The legal regime for the conduct of clinical trials of medicinal products for human use in the European Union is set out in Directive 200120EC (the Clinical Trials Directive


Paying Royalties for Technology that Competitors Can Use for Free - AG Wathelet’s Genentech Opinion
  • McDermott Will & Emery
  • European Union
  • April 28 2016

The Court of Justice of the European Union (CJEU) recently issued its opinion on a question referred to it by the Paris Court of Appeal regarding the


EMEA and FDA focus on clinical research safety and enforcement
  • McDermott Will & Emery
  • European Union, USA
  • August 20 2009

Recent policy changes emphasize the need for sponsoring organizations to be even more vigilant in establishing, updating and monitoring their systems for compliance with clinical research requirements, whether conducted domestically or in a foreign locale


International News: Focus on International Dispute Resolution
  • McDermott Will & Emery
  • Chile, China, European Union, France, USA
  • December 1 2016

In October 2016, the European Commission launched a public consultation to


Lawfulness of new packaging in which drugs are marketed in another EEA state by a parallel importer
  • McDermott Will & Emery
  • European Union
  • March 27 2009

On a reference from the Austrian Supreme Court concerning Article 7 of the Trade Marks Directive (89104EEC) and the parallel importation of pharmaceuticals, the European Court of Justice (ECJ) has followed the lead of Advocate General Sharpston and concluded that the lawfulness of the new packaging, in which drugs are marketed in another European Economic Area (EEA) State by a parallel importer, is to be measured solely against whether it is capable of damaging the reputation of the trade mark and its proprietor


Repackaging and parallel import of pharmaceutical products
  • McDermott Will & Emery
  • European Union
  • May 22 2007

On 27 April 2007, the European Court of Justice (the “ECJ”) handed down yet another decision in the case of Boehringer Ingelheim & others v Swingward Ltd and Dowelhurst Ltd, Case C-34804 (“Boehringer II”


General Court of the EU Confirms Fines Imposed on Lundbeck and Generic Drug Manufacturers for Entering into Patent Settlements
  • McDermott Will & Emery
  • European Union
  • September 22 2016

On 8 September 2016, the General Court of the EU (GCEU) handed down five judgments upholding a decision by the Commission of 19 June 2013 imposing


Commission publishes fourth monitoring report on pharmaceutical patent settlements
  • McDermott Will & Emery
  • European Union
  • February 11 2014

The European Commission has published its fourth Report on the Monitoring of Patent Settlements (the report), concerning pharmaceutical patent


European Court of Justice Rules that a Scottish Law Establishing Minimum Unit Pricing for Alcoholic Drinks May Violate EU Law
  • McDermott Will & Emery
  • European Union
  • December 29 2015

On 23 December 2015, the Court of Justice of the European Union (ECJ) - Europe's highest court - ruled that a Scottish law establishing minimum unit